SEC Form 25-NSE filed by Odonate Therapeutics Inc.

1/25/22 5:30:50 PM ET

$ODT

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ODT alert in real time by email

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

UNITED STATES

OMB APPROVAL

OMB Number:		3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:		1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

333-221533

Issuer:	Odonate Therapeutics, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	4747 Executive Drive, Suite 510
	San Diego	CALIFORNIA	92121
Telephone number:				858-200-3412

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2022-01-25	By	Aravind Menon		Hearings Advisor
Date		Name		Title

¹	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $ODT alert in real time by email

SEC Form 25-NSE filed by Odonate Therapeutics Inc.

1/25/22 5:30:50 PM ET

$ODT

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ODT alert in real time by email

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

UNITED STATES

OMB APPROVAL

OMB Number:		3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:		1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

333-221533

Issuer:	Odonate Therapeutics, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	4747 Executive Drive, Suite 510
	San Diego	CALIFORNIA	92121
Telephone number:				858-200-3412

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

2022-01-25	By	Aravind Menon		Hearings Advisor
Date		Name		Title

¹	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $ODT alert in real time by email

SEC Form 25-NSE filed by Odonate Therapeutics Inc.

Chat with this insight

Recent Analyst Ratings for
$ODT

SEC Form 25-NSE filed by Odonate Therapeutics Inc.

Chat with this insight

Recent Analyst Ratings for
$ODT

$ODT
Press Releases

Fastest customizable press release news feed in the world

Odonate Announces Expected Delisting of Its Stock

Odonate Therapeutics Announces Planned Return of Capital to Stockholders through Share Repurchase Plan

Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021

$ODT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Odonate Therapeutics downgraded by Jefferies with a new price target

Odonate Therapeutics downgraded by Cowen

$ODT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Ecor1 Capital, Llc bought $308,662 worth of shares (185,941 units at $1.66) and sold $9,741,063 worth of shares (5,887,610 units at $1.65)

SEC Form 4: Boxer Capital, Llc sold $623,340 worth of shares (400,000 units at $1.56)

SEC Form 4: Davis Aaron I. sold $2,499,948 worth of shares (1,200,000 units at $2.08)

$ODT
SEC Filings